Phio Pharmaceuticals

PHIONasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$11.617 M

$1.00 -0.99%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

-$8.70M

Loss-making

Shares outstanding

11,617,250

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#421BioLineRxBLRX$11.8M
#422ScientureSCNX$11.7M
#423Phio PharmaceuticalsPHIO$11.6M
#424Kala BioKALA$11.6M
#425Aspire BiopharmaASBP$11.5M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Phio Pharmaceuticals, worth $27.7K. Grants and option exercises are excluded.

Ronald Todd Plott$17.1K
15,000 shares at $1.14 on 19 Aug 2026 · filed 20 Aug 2026
Robert J. BittermanChairman, Pres. & CEO$10.6K
10,000 shares at $1.06 on 18 Aug 2026 · filed 19 Aug 2026

What if Phio Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $30.2T

$2,602,507

Per share 2,602,507× higher

Bitcoin $1.74T

$149,919.74

Per share 149,920× higher

Nvidia $5.52T

$474,791.11

Per share 474,791× higher

Or at a round number

$20.0M $50.0M $100.0M $200.0M

Where these numbers come from

Share counts and financials for Phio Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.